LWM
JAZZ icon

LBA Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

LBA Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$4K Hold
30
– – ﹤0.01% 377
2016
Q4 		$3K Buy
+30
New +$3.34K ﹤0.01% 395

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

LBA Wealth Management's JAZZ Position: Q1 2017 in Review

LBA Wealth Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2017 at 30 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #377.

LBA Wealth Management first reported a position in JAZZ in Q4 2016 and has held it in 2 quarters since. 306 funds tracked by Wall St. Rank hold JAZZ as of Q1 2017.

  • LBA Wealth Management held 30 shares of Jazz Pharmaceuticals worth $4K as of Q1 2017.
  • LBA Wealth Management left its Jazz Pharmaceuticals share count unchanged in Q1 2017.
  • Jazz Pharmaceuticals made up ﹤0.01% of LBA Wealth Management's portfolio in Q1 2017, its #377 holding.
  • LBA Wealth Management first reported a position in Jazz Pharmaceuticals in Q4 2016 and has held it in 2 quarters since.
  • 306 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2017.

Based on LBA Wealth Management's 13F filing for Q1 2017, filed 9 May 2017.